02 Oct2015
CARsgen partners with Shanghai Cancer Institute to develop cancer immunotherapies
The five year partnership will identify and develop novel CAR-T candidates as well as next-generation CAR-T technologies
The five year partnership will identify and develop novel CAR-T candidates
Singapore: China based CARsgen Therapeutics, a private and venture backed company focused on the development of CAR-T-based autologous immunotherapy to treat solid tumors, has partnered with Shanghai Cancer Institute for the advancement of CARsgen’s CAR-T cancer immunotherapeutics.
Tokyo: Japan’s Daiichi Sankyo Company Limited has announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Europe 2015/2016, a collaborative drug discovery initiative for universities and research institutes in Europe.